Cipla Limited
Pharmaceuticals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-14
Cipla: Recent Corporate Announcements — Summary
1. Headwinds and Challenges
- Q1FY27 profitability declined sharply year-on-year.
Revenue from operations rose to INR 7,119 Cr in Q1FY27 from INR 6,957 Cr
in Q1FY26, but EBITDA fell to INR 1,192 Cr (16.7% margin) from INR 1,778
Cr (25.6%), and PAT fell to INR 789 Cr (11.1%) from INR 1,298 Cr
(18.7%). Material cost rose to INR 2,667 Cr from INR 2,171 Cr, and
employee benefits expense rose to INR 1,497 Cr from INR 1,312 Cr.
- Other operating income and other income declined.
Other operating income fell to INR 42 Cr from INR 120 Cr; other income
fell to INR 211 Cr from INR 259 Cr.
- North America requires adaptation to evolving business
dynamics. The segment presentation is framed around adapting to
these dynamics, with gVentolin supply ramp-up planned over coming
quarters following initial shipments.
- South Africa OTC underperformed the market. Cipla
OTC growth was 0.6% against market growth of 3.5%, although the
prescription business (9.8% vs 6.9%) and overall business (6.5% vs 5.7%)
grew faster than the market.
- The AGM MD & GCEO address was titled “Highest-ever
Yearly Revenue Despite Multiple Headwinds,” indicating that
headwinds were present through FY26 even as revenue reached a
record.
- Forward-looking statement risk factors cited in the
investor presentation include risks, uncertainties, pandemic and other
factors, ability to implement strategy, growth and expansion plans,
obtaining regulatory approvals, technological changes, earnings
fluctuation, foreign exchange rates, international operations and
exports, and market risks.
- Leadership transition. Mr Ashish Adukia
relinquished the Global CFO and KMP position effective close of business
on 23 July 2026, transitioning to an internal business leadership role;
Mr Dinesh Jain was appointed Global CFO and KMP effective 24 July
2026.
2. Tailwinds and Growth Prospects
- Highest-ever quarterly revenue. Q1FY27 revenue of
INR 7,119 Cr was described as the highest Q1 revenue; “One India”
recorded its highest-ever quarterly revenue of INR 3,452 Cr.
- India Rx brand strength. 23 brands in IPM Top 300
ranks; 33 brands with revenue above INR 100 Cr; Foracort is the biggest
respiratory brand in IPM at over INR 1,000 Cr; seven therapies hold IPM
Top 5 ranks. Recent launches target priority therapies, including an
anti-allergy respiratory portfolio with Bilastine + Montelukast.
- Consumer brands. One India consumer brands revenue
of INR 481 Cr; South Africa consumer brands revenue of ZAR 405 Mn.
- North America. gProventil ranked No. 1 with 21%
total market share and more than 50 million inhaler units supplied
cumulatively to the U.S.; gVentolin launched in the U.S. during the
quarter with initial shipments executed; recent launches include
Nintedanib, Dapagliflozin and Liraglutide. The ANDA/NDA portfolio totals
278 approved, tentatively approved, under approval and partnered
products across Cipla Ltd, Invagen, PEPFAR and partnered
categories.
- South Africa. Private business revenue of ZAR 906
Mn in Q1FY27; 10 brands with MAT market revenue above ZAR 100 Mn;
highest number of brands in the top 30 (6), top 50 (11) and top 100 (20)
within the generics segment; healthy performance across Respiratory, CNS
and Alimentary TR & Metabolism.
- Biosimilar partnership. Invagen Pharmaceuticals
Inc., a wholly owned subsidiary, entered a strategic partnership with
Qilu Pharmaceutical Co., Ltd. for exclusive licensing and supply of
QL2107, a biosimilar to Keytruda (pembrolizumab), in the United States.
Qilu handles development, regulatory registration and supply; Cipla USA
Inc. handles commercialization. Management stated goals to expand the
biosimilar portfolio in coming fiscal years, launch QL2107 subject to
regulatory approval, and bring a high-quality, affordable pembrolizumab
biosimilar to U.S. patients.
- Inzpera acquisition and amalgamation. Cipla
acquired 100% of Inzpera, adding a differentiated pediatrics and
wellness portfolio. The Scheme of Amalgamation (by Absorption) of
Inzpera Healthsciences Limited into Cipla Limited is proceeding under an
NCLT Mumbai Bench order dated 18 August 2026; the NCLT dispensed with
meetings of equity shareholders and unsecured creditors, and there are
no secured creditors in the Transferee Company.
- Partnerships and innovation. Secured rights from
Eli Lilly to distribute and promote Yurpeak in India; exclusive
marketing and distribution rights for Pfizer brands (Corex, Dolonex,
Neksium, Dalacin C); CGT portfolio (Ciplostem, Regenacip, Xtiktr)
gaining traction in India; launches of Voltido Trio, Afrezza (inhaled
insulin) and Zemdri (Plazomycin); expanded DPI capabilities in the U.S.
and MDI in the U.S. and Morocco.
- Financial strength. Strong $1Bn+ net cash position;
cash and cash equivalents of INR 10,094 Cr as at June 2026; total debt
of INR 600 Cr.
- Quality and ESG. 46 regulatory inspections
completed in FY26 with no critical observations; 82% reduction in Scope
1 and Scope 2 GHG emissions versus FY2019-20; 2.6x water positive; all
Cipla India manufacturing operations ZWTL re-certified; 84% renewable
electricity usage; inclusion in the 2026 Dow Jones Best in Class World
Index; committed to net zero by 2050.
- Investor engagement. Meetings scheduled with
analysts and institutional investors, including the Jefferies India
Forum Conference in Gurgaon on 17 September 2026 and the Kotak
Healthcare Conference in Mumbai on 18 September 2026, both in person,
subject to change due to unforeseen circumstances.
3. Key Risks
- Regulatory approval risk for pipeline products,
including the QL2107 pembrolizumab biosimilar launch, which is subject
to regulatory approval.
- Execution and supply ramp-up risk on gVentolin in
the U.S. over coming quarters.
- Foreign exchange and international operations risk,
including exposure to market risks, as cited in the forward-looking
statement risk factors.
- Profitability pressure evidenced by the Q1FY27
margin contraction and higher material and employee costs.
- Dependence on partner-led products and in-licensing
arrangements for several growth initiatives.
- Scheme of Amalgamation process risk: shareholders
and unsecured creditors have 30 days from receipt of notice to submit
representations to the NCLT, with a simultaneous copy to the registered
office, failing which it will be presumed they have no objection.
- Investor meeting schedule risk: the schedule is
subject to change due to unforeseen circumstances involving the investor
or the company.
Broker Narrative
Brokers evolved from flagging Indore/Goa USFDA scrutiny and
gAdvair/gAbraxane launch delays in 2023 to a 2026 narrative built on
gAdvair/gVentolin approvals and a pembrolizumab biosimilar partnership,
while still citing Pithampur clearance as a key risk. Persistent themes
included regulatory plant delays, Africa tender pressures, US price
erosion, and margin compression. The growth driver mix shifted from
lanreotide and respiratory share gains to GLP-1 branded chronic
therapies, biosimilars, and a higher US filing run-rate, with earlier
earnings estimate cuts replaced by guided FY27 EBITDA margin
expansion.
Fears that came true
- Regulatory clearance delays persisted from Indore/Goa to Pithampur,
and lanreotide was discontinued over partner Pharmathen’s Greece
facility issues, echoing early USFDA fears alongside repeated
DISAPPOINTMENT outcomes and negative actual returns from 2024–2026.
- Marquee launch delays materialized as gAdvair remained pending until
H1FY27, while gRevlimid loss of exclusivity weighed on US sales and API
sales fell ~59% YoY during the 2024–2026 disappointment cluster.
- US price erosion and margin pressure continued, with gross margin
contracting 208 bps YoY to 64.4% and one Africa region hit by loss of
tenders, undermining earnings through the period of negative actual
returns.
Optimism that failed
- Lanreotide’s 17%+ US market-share momentum did not sustain, as it
was discontinued due to regulatory issues at Pharmathen’s Greece
facility, removing a key US growth driver.
- India’s projected 12% revenue CAGR and trade-generics double-digit
growth stalled, with trade generic and consumer portfolios growing
slower and consumer growth only expected to regain double-digit momentum
later.
- SAGA’s Africa outperformance (8.9% vs 4.4% market CAGR) reversed,
with one Africa region impacted by loss of tenders instead of continued
market-beating growth.
Broker Timeline
73 broker calls · 2023-05-12 to 2026-10-28
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞